Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: An ex vivo study

American Journal of Surgical Pathology

Volumn 35, Issue 7, 2011, Pages 949-961

  Al Ahmadie, Hikmat A ^a   Alden, Darym ^a   Fine, Samson W ^a   Gopalan, Anuradha ^a   Touijer, Karim A ^a   Russo, Paul ^a   Reuter, Victor E ^a   Tickoo, Satish K ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

immunohistochemistry; needle biopsy; renal cell carcinoma; renal cortical tumors

Indexed keywords

2 METHYLACYL COENZYME A RACEMASE; ALPHA-METHYLACYL-COA RACEMASE; CA9 PROTEIN, HUMAN; CARBONATE DEHYDRATASE; CYTOKERATIN 7; ISOMERASE; MEMBRANE METALLOENDOPEPTIDASE; STEM CELL FACTOR RECEPTOR; TUMOR ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; HUMAN; IMMUNOHISTOCHEMISTRY; KIDNEY CORTEX; KIDNEY TUMOR; METABOLISM; METHODOLOGY; NEEDLE BIOPSY; NEPHRECTOMY; ONCOCYTOMA; PATHOLOGY;

ADENOCARCINOMA; ADENOMA, OXYPHILIC; ANTIGENS, NEOPLASM; BIOPSY, NEEDLE; CARBONIC ANHYDRASES; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-7; KIDNEY CORTEX; KIDNEY NEOPLASMS; NEPHRECTOMY; NEPRILYSIN; PROTO-ONCOGENE PROTEINS C-KIT; RACEMASES AND EPIMERASES; TUMOR MARKERS, BIOLOGICAL;

EID: 79959677250     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31821e25cd     Document Type: Article

References (57)

1. American Cancer Society. Cancer Facts & Figures 2010. Atlanta; .2010. Available at: http://www.cancer.org/acs/groups/content/ @epidemiologysurveilance/documents/document/acspc-026238.pdf.
2. Tumors of the Kidney. In: Eble JN GS, Epstein JI, Sesterhenn IA, eds. Pathology and Genetics Tumours of the Urinary System and Male Genital Organs. Lyon: IARCPress; 2004:9-87.
3. Abrahams NA, MacLennan GT, Khoury JD, et al. Chromophobe renal cell carcinoma: a comparative study of histological, immunohistochemical and ultrastructural features using high throughput tissue microarray. Histopathology. 2004;45:593-602. (Pubitemid 40029819)
4. Al-Ahmadie HA, Alden D, Qin LX, et al. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Am J Surg Pathol. 2008;32:377-382. (Pubitemid 351398928)
5. Amin MB, Amin MB, Tamboli P, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26:281-291. (Pubitemid 34184451)
6. Avery AK, Beckstead J, Renshaw AA, et al. Use of antibodies to RCC and CD10 in the differential diagnosis of renal neoplasms. Am J Surg Pathol. 2000;24:203-210. (Pubitemid 30078709)
7. Barocas DA, Rohan SM, Kao J, et al. Diagnosis of renal tumors on needle biopsy specimens by histological and molecular analysis. J Urol. 2006;176:1957-1962. (Pubitemid 44633153)
8. Beland MD, Mayo-Smith WW, Dupuy DE, et al. Diagnostic yield of 58 consecutive imaging-guided biopsies of solid renal masses: should we biopsy all that are indeterminate? AJR Am J Roentgenol. 2007;188:792-797.
9. Campbell SC. The paradigm shift in renal mass biopsy. Clin Adv Hematol Oncol. 2008;6:253-254, 258.
10. Cheville JC, Lohse CM, Zincke H, et al. Comparisons of outcome and prognostic features among histologic subtypes of renal cell carcinoma. Am J Surg Pathol. 2003;27:612-624. (Pubitemid 36514472)
11. Dechet CB, Zincke H, Sebo TJ, et al. Prospective analysis of computerized tomography and needle biopsy with permanent sectioning to determine the nature of solid renal masses in adults. J Urol. 2003;169:71-74. (Pubitemid 35461553)
12. Genega EM, Ghebremichael M, Najarian R, et al. Carbonic anhydrase IX expression in renal neoplasms: correlation with tumor type and grade. Am J Clin Pathol. 2010;134:873-879.
13. Hedgepeth RC, Gilbert SM, He C, et al. Body image and bladder cancer specific quality of life in patients with ileal conduit and neobladder urinary diversions. Urology. 2010;76:671-675.
14. Huang WC, Elkin EB, Levey AS, et al. Partial nephrectomy versus radical nephrectomy in patients with small renal tumors: is there a difference in mortality and cardiovascular outcomes? J Urol. 2009;181:55-61.
15. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277-300.
16. Kummerlin I, Ten Kate F, Smedts F, et al. Core biopsies of renal tumors: a study on diagnostic accuracy, interobserver, and intraobserver variability. Eur Urol. 2008;53:1219-1225.
17. Laguna MP, Kummerlin I, Rioja J, et al. Biopsy of a renal mass: where are we now? Cur Opin Urol. 2009;19:447-453.
18. Lam JS, Leppert JT, Figlin RA, et al. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology. 2005;66:1-9. (Pubitemid 41356552)
19. Lam JS, Pantuck AJ, Belldegrun AS, et al. G250: a carbonic anhydrase IX monoclonal antibody. Curr Oncol Rep. 2005;7:109-115. (Pubitemid 40485466)
20. Lebret T, Poulain JE, Molinie V, et al. Percutaneous core biopsy for renal masses: indications, accuracy and results. J Urol. 2007;178: 1184-1188. (Pubitemid 47368414)
21. Lee CT, Katz J, Shi W, et al. Surgical management of renal tumors 4 cm or less in a contemporary cohort. J Urol. 2000;163:730-736. (Pubitemid 30091605)
22. Lee CT, Katz J, Fearn PA, et al. Mode of presentation of renal cell carcinoma provides prognostic information. Urol Oncol. 2002;7:135-140.
23. Mathers ME, Pollock AM, Marsh C, et al. Cytokeratin 7: a useful adjunct in the diagnosis of chromophobe renal cell carcinoma. Histopathology. 2002;40:563-567. (Pubitemid 34621815)
24. Maturen KE, Nghiem HV, Caoili EM, et al. Renal mass core biopsy: accuracy and impact on clinical management. AJR Am J Roentgenol. 2007;188:563-570. (Pubitemid 46167760)
25. McKiernan J, Yossepowitch O, Kattan MW, et al. Partial nephrectomy for renal cortical tumors: pathologic findings and impact on outcome. Urology. 2002;60:1003-1009. (Pubitemid 35447555)
26. Motzer RJ, Bacik J, Mariani T, et al. Treatment outcome and survival associated with metastatic renal cell carcinoma of nonclear- cell histology. J Clin Oncol. 2002;20:2376-2381. (Pubitemid 34441667)
27. Neuzillet Y, Lechevallier E, Andre M, et al. Accuracy and clinical role of fine needle percutaneous biopsy with computerized tomography guidance of small (less than 4.0 cm) renal masses. J Urol. 2004;171:1802-1805. (Pubitemid 38501006)
28. Patel PH, Chadalavada RS, Chaganti RS, et al. Targeting von Hippel-Lindau pathway in renal cell carcinoma. Clin Cancer Res. 2006;12:7215-7220. (Pubitemid 46095391)
29. Patel PH, Chaganti RS, Motzer RJ. Targeted therapy for metastatic renal cell carcinoma. Br J Cancer. 2006;94:614-619. (Pubitemid 43361889)
30. Potter C, Harris AL. Hypoxia inducible carbonic anhydrase IX, marker of tumour hypoxia, survival pathway and therapy target. Cell Cycle. 2004;3:164-167. (Pubitemid 40268690)
31. Reuter VE. Renal tumors exhibiting granular cytoplasm. Semin Diagn Pathol. 1999;16:135-145. (Pubitemid 29357971)
32. Reuter VE. The pathology of renal epithelial neoplasms. Semin Oncol. 2006;33:534-543. (Pubitemid 44511979)
33. Richter F, Kasabian NG, Irwin RJ Jr, et al. Accuracy of diagnosis by guided biopsy of renal mass lesions classified indeterminate by imaging studies. Urology. 2000;55:348-352. (Pubitemid 30110582)
34. Ronnen EA, Kondagunta GV, Ishill N, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer. 2006; 107:2617-2621. (Pubitemid 44845616)
35. Russo P. Open radical nephrectomy for localized renal cell carcinoma. In: Vogelzang NJ, Scardino PT, Shipley WU, et al, eds. Comprehensive Textbook of Genitourinary Oncology. Philadelphia: Lippincott Williams & Wilkins; 2006:725-731.
36. Russo P. Multi-modal treatment for metastatic renal cancer: the role of surgery. World J Urol. 2010;28:295-301.
37. Schmidbauer J, Remzi M, Memarsadeghi M, et al. Diagnostic accuracy of computed tomography-guided percutaneous biopsy of renal masses. Eur Urol. 2008;53:1003-1011.
38. Schmidinger M, Zielinski CC. Novel agents for renal cell carcinoma require novel selection paradigms to optimise first-line therapy. Cancer Treat Rev. 2009;35:289-296.
39. Shah RB, Bakshi N, Hafez KS, et al. Image-guided biopsy in the evaluation of renal mass lesions in contemporary urological practice: indications, adequacy, clinical impact, and limitations of the pathological diagnosis. Hum Pathol. 2005;36:1309-1315. (Pubitemid 41682287)
40. Shannon BA, Cohen RJ, de Bruto H, et al. The value of preoperative needle core biopsy for diagnosing benign lesions among small, incidentally detected renal masses. J Urol. 2008;180: 1257-1261.
41. Skinnider BF, Amin MB. An immunohistochemical approach to the differential diagnosis of renal tumors. Semin Diagn Pathol. 2005; 22:51-68. (Pubitemid 43163179)
42. Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol. 2005; 29:747-754. (Pubitemid 40734424)
43. Snyder ME, Bach A, Kattan MW, et al. Incidence of benign lesions for clinically localized renal masses smaller than 7 cm in radiological diameter: influence of sex. J Urol. 2006;176:2391-2395.
44. Somani BK, Nabi G, Thorpe P, et al. Image-guided biopsydiagnosed renal cell carcinoma: critical appraisal of technique and long-term follow-up. Eur Urol. 2007;51:1289-1295.
45. Theodoropoulos VE, Lazaris A, Sofras F, et al. Hypoxia-inducible factor 1 alpha expression correlates with angiogenesis and unfavorable prognosis in bladder cancer. Eur Urol. 2004;46:200-208. (Pubitemid 38902737)
46. Thuillier C, Long JA, Lapouge O, et al. Value of percutaneous biopsy for solid renal tumours less than 4 cm in diameter based on a series of 53 cases. Prog Urol. 2008;18:435-439.
47. Tickoo SK, Amin MB. Discriminant nuclear features of renal oncocytoma and chromophobe renal cell carcinoma: analysis of their potential utility in the differential diagnosis. Am J Clin Pathol. 1998;110:782-787. (Pubitemid 28541555)
48. Tickoo SK, Milowsky MI, Dhar N, et al. Hypoxia inducible factor (HIF) and mammalian target of rapamycin (mTOR) pathway markers in urothelial carcinoma of the bladder: Possible therapeutic implications. BJU Int. 2011;107:844-849.
49. Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of alphamethylacyl- CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol. 2004;28:69-76. (Pubitemid 38031623)
50. Tu J, Chen Y, Hyjek E, et al. Carbonic anhydrase IX as a highly sensitive and specific marker of clear cell renal cell carcinoma: a comparative immunohistochemical study using a panel of commonly utilized antibodies in the differential diagnosis of renal cell tumors. Mod Pathol. 2005;18:169A-169A.
51. Vasudevan A, Davies RJ, Shannon BA, et al. Incidental renal tumours: the frequency of benign lesions and the role of preoperative core biopsy. BJU Int. 2006;97:946-949.
52. Reuter VE SKT. Adult renal tumors. In: Mills SE DC, Greenson JK, Oberman HA, et al, eds. Sternberg's Diagnostic Surgical Pathology. Philadelphia: Lippincott Williams & Wilkins; 2004:1955-2000.
53. Volpe A, Kachura JR, Geddie WR, et al. Techniques, safety and accuracy of sampling of renal tumors by fine needle aspiration and core biopsy. J Urol. 2007;178:379-386. (Pubitemid 47030509)
54. Wang R, Wood DP Jr. Evolving role of renal biopsy in small renal masses. Urol Oncol. 2009;27:332-334.
55. Wang R, Wolf JS Jr, Wood DP Jr, et al. Accuracy of percutaneous core biopsy in management of small renal masses. Urology. 2009;73:586-590.
56. Wood BJ, Khan MA, McGovern F, et al. Imaging guided biopsy of renal masses: indications, accuracy and impact on clinical management. J Urol. 1999;161:1470-1474. (Pubitemid 29420798)
57. Young AN, Amin MB, Moreno CS, et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol. 2001;158: 1639-1651. (Pubitemid 32422929)